IDEAYA Biosciences
Mili Mandal currently serves as the Director of Clinical Biomarker Sciences in Clinical Development at IDEAYA Biosciences, a position held since June 2023. Previous roles include Associate Director of Translational Science at Artiva Biotherapeutics and Senior Scientist/Group Leader in CAR-T Cancer Immunotherapy at Fate Therapeutics Inc. Additionally, Mili Mandal held a position as Associate Director for the International Immuno-oncology Network Research Liaison at Bristol-Myers Squibb and served as an Investigator in Translational Sciences at GSK. Mili Mandal's early career involved post-doctoral research at Rutgers University and a Medical Cytogenetic Technologist role at West Virginia University Hospital, complemented by graduate research assistant work. Educational achievements include a Ph.D. in Molecular Pathology and Immunology from Rutgers University and two master's degrees in Plant and Soil Sciences and Plant Sciences, respectively.
This person is not in any offices
IDEAYA Biosciences
1 followers
IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California